Hologic, Inc. $HOLX Shares Bought by Aberdeen Group plc

Aberdeen Group plc lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 244,997 shares of the medical equipment provider’s stock after acquiring an additional 6,589 shares during the period. Aberdeen Group plc owned approximately 0.11% of Hologic worth $15,964,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in HOLX. Chung Wu Investment Group LLC acquired a new stake in shares of Hologic in the second quarter worth $26,000. Zions Bancorporation National Association UT acquired a new stake in shares of Hologic in the first quarter worth $34,000. Cromwell Holdings LLC increased its position in shares of Hologic by 307.0% in the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 436 shares in the last quarter. Allworth Financial LP increased its position in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 216 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Hologic in the first quarter worth $42,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.6%

NASDAQ HOLX opened at $65.92 on Wednesday. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The company has a market capitalization of $14.66 billion, a price-to-earnings ratio of 27.35, a price-to-earnings-growth ratio of 2.25 and a beta of 0.63. The company’s fifty day moving average price is $67.06 and its two-hundred day moving average price is $63.38.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the firm posted $1.06 EPS. The firm’s revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.88% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Hologic in a report on Wednesday, October 8th. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. Morgan Stanley raised their price target on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a report on Thursday, July 31st. Evercore ISI set a $78.00 price target on shares of Hologic and gave the company an “outperform” rating in a report on Tuesday, October 7th. Finally, Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and raised their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $80.15.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.